Imperial College London

Professor Marc-Emmanuel Dumas

Faculty of MedicineDepartment of Metabolism, Digestion and Reproduction

Chair in Systems Medicine
 
 
 
//

Contact

 

+44 (0)20 7594 1820m.dumas Website

 
 
//

Location

 

128Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Summary

Professor Marc-Emmanuel Dumas, PhD MEng MSc BEng BSc FRSB FRSC 

Marc-Emmanuel Dumas is Chair in Systems Medicine, jointly appointed between the Department of Metabolism, Digestion and Reproduction and the National Heart and Lung Institute. He is head of the Section of Biomolecular Medicine, which hosts state-of-the-art equipment dedicated to metabolomics, crystallisation science and tissue culture. He founded and is director of Imperial's Microbiome Network, a cross-faculty multidisciplinary network of excellence made of >60 PIs and their groups to consolidate research, teaching and public engagement activities around the microbiome.

Research led by Professor Dumas targets innovative metabolomics approaches to better understand the key challenges in the integrative control of metabolism, blending genomics and microbiomics in systems medicine. He focusses mostly on the role of the microbiome (but not limited to) in metabolic and cardiorespiratory diseases as well as in chronic inflammation, including neuroinflammation, and certain types of cancers.

Since Sept 2020, he is CNRS investigator and group leader at UMR8199 in Lille, France. He also holds an Adjunct Professorship at McGill University's Genome Innovation Centre and Department of Human Genetics in Montréal, Canada.

For a full publication list, please click on my publications page, or check out my Researcher ID page and ORCID for recent citation statistics.


Selected Publications

Journal Articles

Talmor-Barkan Y, Bar N, Shaul AA, et al., 2022, Metabolomic and microbiome profiling reveals personalized risk factors for coronary artery disease, Nature Medicine, Vol:28, ISSN:1078-8956, Pages:295-+

Fromentin S, Forslund SK, Chechi K, et al., 2022, Microbiome and metabolome features of the cardiometabolic disease spectrum, Nature Medicine, Vol:28, ISSN:1078-8956, Pages:303-+

Dejnirattisai W, Huo J, Zhou D, et al., 2022, SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses, Cell, Vol:185, ISSN:0092-8674, Pages:467-484.e15

Belda E, Voland L, Tremaroli V, et al., 2022, Impairment of gut microbial biotin metabolism and host biotin status in severe obesity: effect of biotin and prebiotic supplementation on improved metabolism, Gut, ISSN:0017-5749

Forslund SK, Chakaroun R, Zimmermann-Kogadeeva M, et al., 2021, Combinatorial, additive and dose-dependent drug-microbiome associations, Nature, Vol:600, ISSN:0028-0836, Pages:500-+

Wickenhagen A, Sugrue E, Lytras S, et al., 2021, A prenylated dsRNA sensor protects against severe COVID-19, Science, Vol:374, ISSN:0036-8075, Pages:1-18

Drake TM, Riad AM, Fairfield CJ, et al., 2021, Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study, The Lancet, Vol:398, ISSN:0140-6736, Pages:223-237

COVID-19 Host Genetics Initiative, 2021, Mapping the human genetic architecture of COVID-19, Nature, Vol:600, ISSN:0028-0836, Pages:472-477

Brial F, Chilloux J, Nielsen T, et al., 2021, Human and preclinical studies of the host-gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health., Gut, Vol:70, ISSN:0017-5749, Pages:2105-2114

Molinaro A, Bel Lassen P, Henricsson M, et al., 2020, Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology, Nature Communications, Vol:11

Vieira-Silva S, Falony G, Belda E, et al., 2020, Statin therapy is associated with lower prevalence of gut microbiota dysbiosis, Nature, Vol:581, ISSN:0028-0836, Pages:310-+

Hoyles L, Fernandez-Real J-M, Federici M, et al., 2018, Publisher Correction: Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women, Nature Medicine, Vol:24, ISSN:1078-8956, Pages:1628-1628

Hoyles L, Fernández-Real J-M, Federici M, et al., 2018, Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women., Nat Med, Vol:24, Pages:1070-1080

Hoyles L, Jiménez-Pranteda MJ, Chilloux J, et al., 2018, Metabolic retroconversion of trimethylamine N-oxide and the gut microbiota, Microbiome, Vol:6, ISSN:2049-2618

Plovier H, Everard A, Depommier C, et al., 2017, A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice, Nature Medicine, Vol:23, ISSN:1546-170X, Pages:107-113

Shoaie S, Ghaffari P, Kovatcheva-Datchary P, et al., 2015, Quantifying Diet-Induced Metabolic Changes of the Human Gut Microbiome, Cell Metabolism, Vol:22, ISSN:1932-7420, Pages:320-331

Venkatesh M, Mukherjee S, Wang H, et al., 2014, Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the Xenobiotic sensor PXR and toll-like receptor 4, Immunity, Vol:41, ISSN:1074-7613, Pages:296-310

Dumas ME, Wilder SP, Bihoreau MT, et al., 2007, Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and normoglycemic rat models, Nature Genetics, Vol:39, ISSN:1061-4036, Pages:666-672

Dumas M-E, Barton RH, Toye A, et al., 2006, Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice, Proceedings of the National Academy of Sciences of the United States of America, Vol:103, ISSN:0027-8424, Pages:12511-12516

More Publications